A preparation method and application of platelet-based immune connector

Through platelet-based immune connectors, the chemical bond connection between specific antibodies and platelets or nanocarrier carriers are used to solve the problem that existing immunotherapy has limited effect on solid tumor tumor cells recognition, and effective recognition and response to tumor cells are achieved. The survival time of postoperative mice was significantly prolonged and tumor recurrence and metastasis were inhibited.

CN116159149BActive Publication Date: 2024-11-15SHANGHAI UNIV OF T C M
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310171001.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-27
Publication Date
2024-11-15
Estimated Expiration
2043-02-27

AI Technical Summary

Technical Problem

The existing immunotherapy methods have limited effect on the identification of solid tumor tumor cells, and it is difficult to effectively prevent tumor cell recurrence and metastasis after surgery, especially in cancers with poor prognosis such as lung cancer, which leads to a reduced cancer cure rate.

Method used

Develop a platelet-based immune connector that enhances the recognition of tumor cells by directly connecting specific antibodies to platelets or loading them on nanocarriers. and answer.

Benefits of technology

This immune connector can effectively promote the connection between T cells and tumor cells, enhance the immune response, significantly prolong the survival time of mice after surgery, inhibit tumor recurrence and metastasis, and improve the effect of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116159149B_ABST
    Figure CN116159149B_ABST
Patent Text Reader

Abstract

The present invention discloses a preparation method and application of a platelet-based immune connector. The immune connector comprises platelets and specific antibodies; the platelets and specific antibodies are directly connected by chemical bonds, or the specific antibodies are loaded through nanocarriers and then connected to platelets. After being injected into the body, the immune connector can simultaneously bind to immune cells and tumor cells to exert an immune enhancement effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a platelet-based immune connector and its application. Background Art

[0002] Surgical resection is currently the first choice for the treatment of most solid tumors. However, postoperative recurrence is a direct factor that reduces the cure rate of cancer. For example, lung cancer, the world's largest cancer, has a particularly poor prognosis. For patients who undergo surgical resection of tumor tissue, if no adjuvant treatment is performed, the recurrence rate will exceed 50%. In order to avoid cancer recurrence, postoperative adjuvant therapy has become an important means of cancer treatment.

[0003] Immunotherapy is a new treatment method that has developed rapidly in recent years. It aims to activate the human immune system, rely on autoimmunity to kill tumor cells, and play a long-term "surveillance" role. For example, chimeric antigen receptor T cell immunotherapy (CAR-T) and immune checkpoint blockade therapy (ICB) have been widely used in tumor treatment. However, due to the limited recognition of tumor cells by immune cells and the widespread immunosuppressive factors in the body, the ultimate effect of immunotherapy is limited.

[0004] In recent years, researchers have developed bispecific antibodies (BiTEs) based on T cells, which can direct T cells to tumor cells, enhance the full "contact" between the two, and improve the recognition of tumor cells by T cells. However, in clinical practice, the indications of BiTEs are extremely limited. Currently, they are only effective for some hematological tumors, and the high heterogeneity of solid tumor cells has greatly increased the difficulty of developing BiTEs for solid tumors.

[0005] Platelets are a type of blood cell in the human body that has functions such as hemostasis and endothelial repair. Studies in recent years have shown that platelets can adhere to tumor cells and play an important role in mediating the invasion and migration of residual tumor cells (circulating tumor cells) after surgery. It is generally believed that P-selectin on the surface of platelets can recognize the surface antigens of tumor cells, and by activating the "adhesion" effect of platelets, circulating tumor cells with invasion and migration capabilities are adhered to the blood vessel wall. This platelet-mediated tumor cell adhesion mechanism has been widely studied and recognized. Therefore, the development of immune connectors based on the adhesion mechanism of platelets to tumor cells can be applied to the postoperative adjuvant treatment of a variety of solid tumors, enhance the recognition and response of immune cells to circulating tumor cells of solid tumors, and use the body's immunity to inhibit postoperative recurrence and metastasis of tumors. Summary of the invention

[0006] The object of the present invention is to provide a platelet-based immune connector and its application.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] An immune connector, including platelets and specific antibodies;

[0009] The platelets and specific antibodies are directly connected by chemical bonding, or the specific antibodies are loaded through nanocarriers and then connected to the platelets;

[0010] The specific antibody is selected from one or more of anti-CD3, anti-CD4, anti-CD8, anti-CD45, anti-CD11b, anti-CD11c, anti-CD27, anti-CD56, anti-CD16, anti-CD15, anti-CD13, anti-CD14, anti-CD64, anti-CD62L, anti-CD19, anti-CD20, anti-CD22, anti-CD33, anti-CD123 or anti-CD44.

[0011] Furthermore, the chemical bond bonding method is selected according to the functional groups carried by the platelets and specific antibodies, such as maleimide / thiol, N-hydroxysuccinimide / amino, azide / alkyne, aldehyde / amino, butadiene / ethylene, biotin / avidin and other click chemistry reactions.

[0012] Furthermore, the nanocarrier is selected from liposomes, solid lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles or polymer micelles.

[0013] In one embodiment of the present invention, anti-CD3 is modified by maleimide group to react and bond with thiol group on the surface of platelet. In another embodiment of the present invention, anti-CD3 is loaded on the surface of nanocarrier liposome and then connected with platelet.

[0014] The above-mentioned immune connector can be used as a drug for tumor immunotherapy.

[0015] The immune connector of the present invention can be applied to the development of immune cell and tumor cell connectors in tumor immunotherapy, wherein the immune cells include T cells, B cells, NK cells, macrophages, neutrophils, and dendritic cells; the tumor cells include brain tumor cells, liver cancer cells, lung cancer cells, esophageal cancer cells, gastric cancer cells, breast cancer cells, pancreatic cancer cells, thyroid cancer cells, nasopharyngeal cancer cells, ovarian cancer cells, renal cancer cells, prostate cancer cells, colorectal cancer cells, and head and neck cancer cells.

[0016] The above-mentioned immune connector can be used as a drug for postoperative treatment of tumors.

[0017] The above-mentioned immune connector is used as a sensitizer for tumor immunotherapy, chemotherapy and radiotherapy.

[0018] The present invention uses platelets as carriers and constructs immune connectors by modifying functional antibodies that can specifically recognize immune cells. After being injected into the body, the immune connectors can simultaneously bind to immune cells and tumor cells to play an immune enhancement role. At the same time, the immune connectors can also be used to prevent postoperative recurrence of solid tumors or to prevent metastasis of solid tumors that cannot be surgically removed, and can also be used as sensitizers in combination with other chemotherapy drugs or immunotherapy drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the preparation route of the platelet-based immune connector of the present invention.

[0020] Figure 2 This is a scanning electron micrograph of the natural platelets and immune connector in Example 6.

[0021] Figure 3 The results of the connection between T cells and tumor cells mediated by the immunoconnector in Example 7. The color represents the tumor cell nucleus and the T cell nucleus; the arrow represents the T cell.

[0022] Figure 4 This is the in vivo efficacy of the immune connector in Example 8 in inhibiting tumor recurrence after surgery.

[0023] Figure 5 The in vivo efficacy of the immune connector in Example 9 in inhibiting postoperative tumor cell metastasis. DETAILED DESCRIPTION

[0024] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples, but it should not be construed as limiting the present invention. Without departing from the spirit and substance of the present invention, the modification or replacement of the method, steps or conditions of the present invention all belong to the scope of the present invention. The experimental methods and reagents without specifying the specific conditions in the examples are all in accordance with the conventional conditions in the art.

[0025] Example 1-5 Preparation of Platelet Immunoconnector

[0026] Example 1

[0027] The preparation of platelet-based immunoconnectors mainly includes two steps, namely, platelet extraction and connection with antibodies with specific recognition functions. The representative process is as follows: Figure 1 .

[0028] Platelets were first extracted from the blood by centrifuging fresh whole blood at 200 g for 20 minutes to obtain platelet-rich plasma, and then the platelet-rich plasma was further centrifuged at 800 g for 20 minutes to obtain platelets.

[0029] 1×108 Each platelet was resuspended in 200 μL of phosphate buffer containing Traut's Reagent (0.1 mg / mL) and alprostadil (alprostadil concentration 1 μM), and the supernatant was removed by centrifugation after reaction for 30 minutes to obtain thiolated platelets; aCD3 was reacted with protein cross-linker 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester (SMCC) at a molar ratio of 1:1.2 at 4°C for 2 hours, and after the reaction, free SMCC was removed by ultrafiltration to obtain maleimidized aCD3-Mal, and then aCD3-Mal was reacted with thiolated platelets in phosphate buffer containing alprostadil for 1 hour, and the CD3-modified platelet immune connector P-aCD3 was obtained after centrifugation to remove the supernatant.

[0030] Example 2

[0031] Preparation of thiolated platelets: 1×10 8 Each platelet was resuspended in 200 μL of phosphate buffer containing Traut's Reagent (0.1 mg / mL) and alprostadil (alprostadil concentration 1 μM), reacted for 30 minutes, and centrifuged to remove the supernatant to obtain thiolated platelets.

[0032] Preparation of aCD3 modified liposomes: aCD3 and DSPE-PEG-NHS were reacted at a molar ratio of 1 to 1.2 at 4°C for 2h to obtain DSPE-PEG-aCD3; subsequently, liposomes with surface modified aCD3 were prepared by thin film hydration method. Liposome formula: DSPE-PEG-aCD3, cholesterol, egg yolk phospholipids, DSPE-PEG-Mal, mass ratio of 1:5:40:1; preparation process: first, cholesterol, egg yolk phospholipids, DSPE-PEG-Mal were dissolved in an appropriate amount of dichloromethane, dichloromethane was removed by rotary evaporation at 37°C, a uniform film was formed on the bottle wall, an aqueous solution containing the prescribed amount of DSPE-PEG-aCD3 was added and hydrated at 37°C for 1h, and the hydrated suspension was subjected to probe ultrasound in an ice bath for 5min to obtain liposomes with surface modified aCD3.

[0033] Preparation of aCD3 modified platelets: Liposomes and thiolated platelets were reacted in phosphate buffer containing alprostadil for 1 hour, and the immunoconnector P-aCD3 was obtained after centrifugation and removal of the supernatant.

[0034] Example 3

[0035] 2×10 8Each platelet was resuspended in 300 μL of phosphate buffer containing Traut's Reagent (0.2 mg / mL) and alprostadil (alprostadil concentration 2 μM), and the supernatant was removed by centrifugation after reaction for 30 minutes to obtain thiolated platelets; aCD56 was reacted with protein crosslinker SMCC at a molar ratio of 1:1.2 at 4°C for 2 hours, and after the reaction, free protein crosslinker SMCC was removed by ultrafiltration to obtain maleimidized aCD56-Mal, and then aCD56-Mal was reacted with thiolated platelets in phosphate buffer containing alprostadil for 1 hour, and the CD56-modified platelet immune connector P-aCD56 was obtained after centrifugation to remove the supernatant.

[0036] Example 4

[0037] The platelets were resuspended in a phosphate buffer containing alprostadil (alprostadil concentration 1 μM), diphenylcyclooctyne-polyethylene glycol-succinimidyl succinate (DBCO-PEG-NHS) was added, and after reacting for 30 minutes, the supernatant was removed by centrifugation to obtain alkynylated platelets;

[0038] aCD16 was reacted with azide-polyethylene glycol 1000-maleimide (N3-PEG1000-Mal) at room temperature for 1 hour, and the free N3-PEG1000-Mal was removed by ultrafiltration to obtain azidated aCD16-N3; aCD56 was reacted with azide-polyethylene glycol 1000-maleimide (N3-PEG1000-Mal) at room temperature for 1 hour, and the free N3-PEG1000-Mal was removed by ultrafiltration to obtain azidated aCD56-N3.

[0039] aCD16-N3 and aCD56-N3 (molar ratio 1:1) were added to the phosphate buffer in which alkynylated platelets were suspended, and the unattached antibodies were removed by centrifugation after 1 hour of reaction to obtain the CD16 and CD56 double-modified immunoconnector P-aCD16 / aCD56.

[0040] Example 5

[0041] 1×10 8 Each platelet was resuspended in 200 μL of phosphate buffer containing Traut's Reagent (0.1 mg / mL) and alprostadil (alprostadil concentration 1 μM), reacted for 30 minutes, and then centrifuged to remove the supernatant to obtain thiolated platelets; maleimide-polyethylene glycol-aldehyde (Mal-PEG-CHO) was added to the phosphate buffer containing the thiolated platelets, and then centrifuged to obtain aldehyde-modified platelets after reacting for 1 hour;

[0042] aCD11c was reacted with aldehyde-modified platelets in a phosphate buffer at pH 7.4 for 1 hour, and the supernatant was removed by centrifugation to obtain the CD11c-modified platelet immunoconnector P-aCD11c.

[0043] Example 6 Structural Characterization of Platelet-Based Immunoconnectors

[0044] The structure of the platelet immunoconnector was observed using scanning electron microscopy, such as Figure 2 As shown, the platelet immune connector P-aCD3 is spherical in shape.

[0045] Example 7 Immunoconnector-mediated T cell-tumor cell connection

[0046] First, platelet immunoconnector (P-aCD3) was prepared according to the method in Example 1, and then platelets (PLT) and platelet immunoconnector (P-aCD3) were labeled with fluorescent dye FITC to obtain PLT-FITC and P-aCD3-FITC. After PLT-FITC and PLT-aCD3-FITC were treated with thrombin (2U / mL) for 30 minutes, the treated PLT-FITC and PLT-aCD3-FITC were incubated with melanoma cells (B16F10) for 4 hours, washed twice with PBS, and then T cells were added and incubated for another 2 hours. After washing twice with PBS, 100 μL DAPI was added for staining for 30 minutes and observed under a confocal microscope.

[0047] like Figure 3 As shown, the tumor cells and T cells in the natural platelet group are distributed relatively independently, while the tumor cells and T cells in the immune connector group are clearly connected. This structure shows that the immune connector can effectively mediate the connection between T cells and tumor cells.

[0048] Example 8 Evaluation of the efficacy of immunoconnectors in inhibiting postoperative tumor recurrence

[0049] Model construction: C57BL / 6 mice were subcutaneously injected with 1×10 7 B16F10 cells, 7 days later, the mice were anesthetized with tribromoethanol solution, and the subcutaneous tumor tissue was surgically removed to establish a mouse tumor postoperative model.

[0050] After surgery, mice in each group were treated as follows: tail vein injection of normal saline, aPD-L1, immune connector (Example 1), immune connector (Example 1) + aPD-L1, the doses in the above groups were: immune connector 10 8 The mice in each group were treated with aPD-L of 12.5 mg / kg and the survival period of each group was recorded.

[0051] like Figure 4As shown, mice in the saline group relapsed rapidly after surgery and all died on the 26th day after surgery. In contrast, 66.7% of the immune connector + aPD-L1 mice were still alive on the 60th day after surgery, and the survival time of the mice was significantly prolonged compared with the group using aPD-L1 and immune connector alone, indicating that the immune connector can enhance the efficacy of immune checkpoint inhibitors and has a good effect in inhibiting tumor recurrence after surgery.

[0052] Example 9 Evaluation of the efficacy of immunoconnectors in inhibiting postoperative tumor metastasis

[0053] Model construction: C57BL / 6 mice were subcutaneously injected with 1×10 7 B16F10 cells were injected into the tail vein 6 hours after suturing. 5 B16F10 tumor cells (luciferase labeled) were cultured to construct a postoperative tumor cell metastasis model.

[0054] The mice in each group were treated with the following treatments: saline, aPD-L1, immune connector (Example 1), immune connector (Example 1) + aPD-L1, and the doses in the above groups were: immune connector 10 8 / piece, aPD-L1 2.5mg / kg.

[0055] like Figure 5 As shown, the survival period of mice in the group treated with immune connector + aPD-L1 was significantly better than that in other experimental groups, indicating that the strategy of combining immune connector with immune checkpoints can inhibit postoperative tumor cell metastasis.

Claims

1. An immune connector, characterized in that: Formed by the connection of platelets and specific antibodies; The platelets and specific antibodies are directly connected by chemical bonding, or the specific antibodies are loaded through nanocarriers and then connected to the platelets; The specific antibody is anti-CD3; The chemical bond bonding method is selected according to the functional groups carried by the platelets and the specific antibodies, and the chemical bond bonding is selected from maleimide / sulfhydryl, N-hydroxysuccinimide / amino, azide / alkyne, aldehyde / amino, butadiene / ethylene, biotin / avidin or other click chemistry reactions.

2. The immune connector according to claim 1, characterized in that: The nanocarrier is selected from liposomes, solid lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles or polymer micelles.

3. Use of the immunoconnector according to claim 1 in the preparation of tumor immunotherapy products.

4. Use of the immune connector according to claim 1 in the preparation of postoperative tumor treatment products.

5. Use of the immunoconnector according to claim 1 in the preparation of a tumor therapy sensitizer.